Assessing Metabolic Changes in Response to mTOR Inhibition in a Mantle Cell Lymphoma Xenograft Model Using AcidoCEST MRI
Author
Akhenblit, Paul J.Hanke, Neale T.
Gill, Alexander
Persky, Daniel O.
Howison, Christine M.
Pagel, Mark D.
Baker, Amanda F.
Affiliation
Univ Arizona, Canc Biol Grad Interdisciplinary ProgramUniv Arizona, Ctr Canc
Univ Arizona, Dept Med Imaging
Issue Date
2016-05-02
Metadata
Show full item recordPublisher
SAGE PublicationsCitation
Akhenblit, P. J., Hanke, N. T., Gill, A., Persky, D. O., Howison, C. M., Pagel, M. D., & Baker, A. F. (2016). Assessing metabolic changes in response to mTOR inhibition in a mantle cell lymphoma xenograft model using acidoCEST MRI. Molecular imaging, 15, 1536012116645439.Journal
Molecular ImagingRights
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
AcidoCEST magnetic resonance imaging (MRI) has previously been shown to measure tumor extracellular pH (pHe) with excellent accuracy and precision. This study investigated the ability of acidoCEST MRI to monitor changes in tumor pHe in response to therapy. To perform this study, we used the Granta 519 human mantle cell lymphoma cell line, which is an aggressive B-cell malignancy that demonstrates activation of the phosphatidylinositol-3-kinase/Akt/mammalian target of rapamycin ( mTOR) pathway. We performed in vitro and in vivo studies using the Granta 519 cell line to investigate the efficacy and associated changes induced by the mTOR inhibitor, everolimus (RAD001). AcidoCEST MRI studies showed a statistically significant increase in tumor pHe of 0.10 pH unit within 1 day of initiating treatment, which foreshadowed a decrease in tumor growth of the Granta 519 xenograft model. AcidoCEST MRI then measured a decrease in tumor pHe 7 days after initiating treatment, which foreshadowed a return to normal tumor growth rate. Therefore, this study is a strong example that acidoCEST MRI can be used to measure tumor pHe that may serve as a marker for therapeutic efficacy of anticancer therapies.Note
Open access journalISSN
1536-0121EISSN
1536-0121Version
Final published versionae974a485f413a2113503eed53cd6c53
10.1177/1536012116645439
Scopus Count
Collections
Except where otherwise noted, this item's license is described as © The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License.